Siltuximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | IL-6 |
| Clinical data | |
| Trade names | Sylvant |
| Other names | CNTO 328 |
| License data |
|
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6450H9932N1688O2016S50 |
| Molar mass | 144983.21 g·mol−1 |
| (what is this?) (verify) | |
Siltuximab (INN[4]), sold under the brand name Sylvant, is used for the treatment of people with multicentric Castleman's disease.[2][3] It is a chimeric (made from human and mouse proteins) monoclonal antibody that binds to interleukin-6. It is an interleukin-6 (IL-6) antagonist.[2]
The common adverse reactions include pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection.[5]
In April 2014, siltuximab was approved for medical use in the United States for the treatment of people with multicentric Castleman's disease who do not have human immunodeficiency virus (HIV) or human herpesvirus-8 (HHV-8).[5][6]
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
- ^ a b c "Sylvant- siltuximab injection, powder, for solution". DailyMed. 21 February 2024. Retrieved 8 June 2024.
- ^ a b "Sylvant EPAR". European Medicines Agency. 30 November 2007. Archived from the original on 24 June 2021. Retrieved 8 June 2024.
- ^ World Health Organization (2009). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 62". WHO Drug Information. 23 (2). hdl:10665/74420.
- ^ a b "Siltuximab". U.S. Food and Drug Administration (FDA). 23 April 2014. Archived from the original on 3 June 2014. This article incorporates text from this source, which is in the public domain.
- ^ "Sylvant (siltuximab)". accessdata.fda.gov. 28 September 2015. Archived from the original on 8 February 2024. Retrieved 8 June 2024.